Objective: To investigate the expression of cortactin in colorectal cancer and its correlation with clinicopathological parameters and prognosis. Methods: The expressions of cortactin in normal colorectal mucosal tissue and colorectal cancer tissue in paraffin-embedded tissue microarray from 319 patients who were diagnosed as colorectal cancer and treated in Cancer Hospital of Chinese Academy of Medical Sciences from 2006 to 2009 was detected by immunohistochemistry. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox proportional risk regression model was used for multivariate analysis. Results: The positive expression rates of cortactin in colorectal cancer tissue and normal colorectal mucosal tissue were 61.1% (195/319) and 5.6% (18/319, P<0.001), respectively. T-stage, N-stage, American Joint Committee on Cancer (AJCC) stage, degree of tumor differentiation, neural invasion and preoperative carcinoembryonic antigen (CEA) levels were associated with the expression of cortactin (P<0.05). The positive expression of cortactin was associated with poorer disease-free survival (P=0.036) and overall survival (P=0.043), and the effect was more significant in patients with stage Ⅱ to Ⅲ. For patients with stage Ⅱ-Ⅲ colorectal cancer, postoperative adjuvant therapy was associated with disease-free survival (P=0.007) and overall survival (P=0.015). The vascular tumor embolus, pathological type, preoperative CEA level and cortactin expression were independent influencing factors for disease-free survival (P<0.05). The age, AJCC stage, preoperative CEA level and cortactin expression were independent influencing factors for overall survival (P<0.05). Preoperative CEA level and cortactin expression were independent influencing factors for disease-free survival and overall survival (P<0.05). Conclusion: Cortactin is expressed in colorectal cancer and in stage Ⅱ-Ⅲ patients, it is a potential predictor of colorectal cancer prognosis.
目的： 探讨皮动蛋白(cortactin)在结直肠癌中的表达及其与临床病理特征和预后的关系。 方法： 选取2006—2009年于中国医学科学院肿瘤医院确诊为结直肠癌并接受治疗的患者319例，利用免疫组化技术检测组织芯片中正常结直肠黏膜组织和结直肠癌组织中cortactin的表达，生存分析采用Kaplan-Meier法和Log rank检验，多因素分析采用Cox比例风险回归模型。 结果： cortactin在结直肠癌组织和正常结直肠黏膜组织中的阳性表达率分别为61.1%(195/319)和5.6%(18/319，P<0.001)。T分期、N分期、美国癌症联合委员会(AJCC)分期、肿瘤分化程度、神经侵犯和术前癌胚抗原(CEA)水平与cortactin表达状态有关(均P<0.05)。在Ⅱ~Ⅲ期患者中，cortactin阳性表达与较差的无病生存(P＝0.036)和总生存(P＝ 0.043)有关。对于Ⅱ~Ⅲ期结直肠癌患者，术后辅助治疗与无病生存(P＝0.007)和总生存(P＝0.015)有关。脉管瘤栓、病理类型、术前CEA水平和cortactin表达状态为无病生存的独立影响因素(均P<0.05)，年龄、AJCC分期、术前CEA水平和cortactin表达状态是总生存的独立影响因素(均P<0.05)，术前CEA水平和cortactin表达状态为无病生存和总生存的独立影响因素(均P<0.05)。 结论： cortactin在结直肠癌组织中表达，在Ⅱ~Ⅲ期结直肠癌患者中，cortactin是一个潜在的预后因子。.
Keywords: Adjuvant chemoradiotherapy; Colorectal neoplasms; Cortactin; Prognosis; Tissue microarray.